Clinical Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Rapid Antigen Tests During the Omicron Wave in South Africa. Academic Article uri icon

Overview

abstract

  • We evaluated the performance of nasal and nasopharyngeal Standard Q COVID-19 [coronavirus disease 2019] Ag tests (SD Biosensor) and the Panbio COVID-19 Ag Rapid Test Device (nasal; Abbott) against the Abbott RealTime severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assay during the Omicron (clades 21M, 21K, and 21L) wave in South Africa. Overall, all evaluated tests performed well, with high sensitivity (range, 77.78%-81.42%) and excellent specificity values (>99%). The sensitivity of rapid antigen tests increased above 90% in samples with cycle threshold <20, and all 3 tests performed best within the first week after symptom onset.

publication date

  • October 17, 2022

Research

keywords

  • COVID-19
  • SARS-CoV-2

Identity

PubMed Central ID

  • PMC9384653

Scopus Document Identifier

  • 85138656459

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiac333

PubMed ID

  • 35921539

Additional Document Info

volume

  • 226

issue

  • 8